

Breast Disease-Oriented Team

Clinical Research Treatment Trial Flowchart
CRC Contact: GRP - CTU Breast Coordinators (CTUBreastCRC@hs.uci.edu)
Clinical Research Manager: Juan Miranda

ALL

UCI 24-05

Riluzole PO vs. Placebo PO
Perceived worsening of *cognitive function*

BREAST COHORT FULL

PI: Chan

CRC: Randy Kang

Accrual: 26/39

UCI 25-48

Riluzole PO vs. Placebo PO
Perceived worsening of cognitive function

PI: Chan

CRC: Madeleine Phan

Accrual: 4/20



HER2+

HER2-

SWOG S2206 (HER2-/low/equivocal)

Arm 1: SOC AC-T

Arm 2: SOC AC-T + Durvalumab (IgG1k mAb)

MammaPrint Index Score MP2 required

PI: Parajuli

CRC: Madeleine Phan

Accrual: 4/10

UCI 25-48

Riluzole PO vs. Placebo PO

Perceived worsening of cognitive function

PI: Chan

CRC: Madeleine Phan

Accrual: 0/20



HR+

UCI 25-213 (PIKALO-2)
 LY4064809 + CDK4/6 Inhibitor + ET
 For aBC PIK3CA

PI: Parajuli
 CRC: TBD
 Accrual: 0/5

UCI 23-192 (WIDER)
 Ribociclib 400mg + SOC ET +
 Goserelin or Leuprolide
 Exploratory cohort is same
 treatment

PI: Parajuli
 CRC: Stephany Ruiz
 Accrual: 14/20

ER+

UCI 24-116 (ELEGANT)
 Arm A: Elacestrant PO (SERD)
 Arm B: Physician's choice endocrine
 Tx

PI: Parajuli
 CRC: Juan Miranda
 Accrual: 0/5



■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

HER2+

A012303 (Any HR)

Arm 1: Trastuzumab +/- Pertuzumab every 3wks for 12months

Arm 2: Trastuzumab +/- Pertuzumab every 3wks for 6 months

PI: Lavasani
CRC: Randy Kang
Accrual: 0/5

TNBC

**1L+****UCI 19-145 (HR+/HER2-)**

CDK 4/6 inhibitor+ER Regulator+Aromatase Inhibitor

CRCs: Stephany Ruiz, Michael Rodriguez, Madeleine Phan
Accrual: 21/40

UCI 25-213 (PIKALO-2)

LY4064809 + CDK4/6 Inhibitor + ET
For aBC PIK3CA

PI: Parajuli
CRC: TBD
Accrual: 0/5

2L+**UCI 22-09 (TNBC, HR+/HER2-)**

XMT-1660 (ADC) – BC, EC, OC, ACC-I

Dose Esc, Backfill Cohort, Exp

SLOT RSVP REQ (HR+ COHORT TEMP CLOSED)

PI: Parajuli
CRC: Juan Miranda
Accrual: 7/10

2L+

**UCI 24-49 (HER2+ IHC 2-3+,
HER2 Amp ISH)**

SLOT RSVP REQ (Dose Esc)

Dose Esc (Ph Ib):

Cohort A: Zongertinib (BI
1810631; HER2 inhibitor) + T-
DM1

Cohort B: BI 1810631 + T-DXd

Cohort K:

Zongertinib+Trastuzumab

PI: Dayyani
CRC: Randy Kang
Accrual: 3/10

UCI 23-109 (HER2 IHC $\geq 1+$)

Cohort A: HER2-Low: Disitamab Vedotin (ADC) vs. DV +
Tucatinib

Cohort B: HER2+: DV vs. DV + Tucatinib

SLOT RSVP REQ (Dose Esc)

PI: Dr. Parajuli

CRC: My Nguyen; Breast CRC TBD
Accrual: 2/10

UCI 25-81/UCI 25-81-03 (HER2+)

*Locally adv or Mets HER2+ prior T-DXd relapsed in 6month
Physician Choice then either Cohort 1 or 2*

Cohort 1: Evorpaccept (ALX148)+Trastuzumab+Chemo

Cohort 2: Trastuzumab+Chemo

PI: Parajuli
CRC: TBD
Accrual: 0/5



METASTATIC: 1L+

UCI 22-09 (TNBC, HR+/HER2-)

XMT-1660 (ADC) – BC, EC, OC, ACC-I

Dose Esc, Backfill Cohort, Exp

SLOT RSVP REQ (HR+/ COHORT TEMP CLOSED)

PI: Parajuli

CRC: Juan Miranda

Accrual: 6/10

ETCTN 10546

ASTX727 (Cytidine deaminase (CDA) inhibitor +
nucleoside hypomethylating agent (HMA)) + Paclitaxel +
Pembrolizumab

DL-2 now open for TNBC

SLOT RSVP REQ

PI: Parajuli

CRC: Randy Kang

Accrual: 1/5

UCI 24-08

SPEDOX-6 IV

SLOT RSVP REQ

PI: Chow

CRC: Erin Torrison; Breast CRC TBD

Accrual: 6/67

PF-08046054 (an ADC) monotherapy

Dose ESC (Part A) or Schedule Optimization (Part B):

PD-L1 expression ≥ 1 TPS, CPS, or % IC

Signal-seeking cohort: ADC monotherapy

Biology cohort: ADC monotherapy

PI: Nagasaka

CRC: TBD

Accrual: 0/6

METASTATIC: 1L+



ALL

UCI 25-106

BMS-986517 Monotherapy
HR+/Her2- and TNBC

PI: Dr. Nabar
Coord: N. Arechiga/TBD
Accrual: 0/5

UCI 24-197

TNG456 Monotherapy or Combined w/Abemaciclib in
solid tumors with MTAP Loss
SLOT RSVP REQ

CRC: TBD
PI: Park
Accrual: 0/5

UCI 24-142

Phase 1 Dose Esc

Group A: VET3-TGI monotherapy by ITu injection

Group C: VET3-TGI monotherapy by IV infusion

Group B: VET3-TGI by ITu injection, Group D: VET3-TGI IV
infusion combo with pembrolizumab

SLOT RSVP REQ

PI: Uchio
CRC: TBD
Accrual: 0/4



ALL

UCI 22-26

CB-03-10 (PO; AR and GR antagonist)

Part 1 (esc): adv/met solid tumor

Part 2 (exp): adv/met solid tumor or relapsed/refractory

TNBC

SLOT RSVP REQ

HPB/Panc CRC: Miranda Duron

Breast CRC: TBD

PI: Dayyani

Accrual: 11/12

UCI 25-75

CRN09682 IV (an MMAE) for SST2-expressing solid tumors

CRC: TBD

PI: Dayyani

Accrual: 0/15

NRG CC014

SOC vs SOC + RT for High-risk Asymptomatic Bone

Metastases

SLOT RSVP REQ

PI: Harris

CRC: Natalie Arechiga; Breast CRC TBD

Accrual: 4/10



Other Interventional/LTFU

UCI 25-43

Type 1 Hybrid Effectiveness of a Patient-Reported Outcomes

PI: Chan
CRC: TBD
Accrual: 0/5

UCI 24-87

Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Patients with Solid Tumors

PI: Arter
CRC: TBD
Accrual: 0/5

A232403

Longitudinal Screening for Financial Hardship to Improve Outcomes in Patients with Advanced Cancer

PI: Lavasani
CRC: TBD
Accrual: 0/5

NRG CC015

E-Mindfulness for living after Breast cancer

PI: Kim
CRC: Jerar
Accrual: 0/10

UCI 24-87

Effect of a Methionine-Reduced Diet in Patients with Solid Tumors

PI: Arter
CRC: Keagan
Accrual: 2/25



BASIC SCIENCE

UCI 18-136

6 slots for Cohort 1/neo-adjuvant and 13 slots for Cohort 2/adjuvant
PI: Parajuli
CRC: Caylee Carlton
Accrual: 79/100

UCI 17-05 (BRCA1 -/-, +/-)

PI: Parajuli
CRC: Billy Joel Sanchez
Accrual: 49/75

Alliance A232403

DOT Approved
Financial Hardship study
PI: Lavasani
CRC: TBD
Accrual: 0/5

SUPPORTIVE CARE

UCI 24-64

High fiber diet as therapy response and reduce recurrence

PI: Whiteson
CRC: TBD
Accrual: 0/60

UCI 25-83

Mobile Health Intervention to Improve Adherence to Oral Anticancer Therapy
PI: Sadigh
CRC: TBD
Accrual: 8/30

UCI 25-115

Couples Intervention for Young Adult Cancer Survivors: A Pilot Study
PI: Hoyt
CRC: TBD
Accrual: 0/5



HEALTH SERVICES RESEARCH

UCI 25-25

PI: Eakin
CRC: TBD
Accrual: 0/150